Preoperative Mean Corpuscular Hemoglobin Concentration (MCHC) as Indicators of Patients' Poor Prognosis for Renal Clear Cell Carcinoma

Ou K#, Shao Y#, Chen C* and Zhuang Q*

Department of Urology, The Third Affiliated Hospital of Soochow University, China
#These authors contributed equally to this work

^*Correspondance to: Qianfeng Zhuang 

 PDF  Full Text DOI: 10.25107/2474-1647.3599

Abstract

Introduction: Low Mean Erythrocyte Hemoglobin Concentrations (MCHC) has been linked to tumor oxygenation issues and anemia connected to cancer, according to studies. It is unknown, though, what role MCHC plays in renal cell cancer patients. In this study, Clear Cell Renal Cell Carcinoma (CCRCC) patients had their preoperative MCHC evaluated for its predictive usefulness. Materials and Methods: Patients diagnosed with CCRCC and undergoing nephrectomy at our institution between 2003 and 2012 were included in the retrospective analysis. Preoperative MCHC was correlated with clinicopathological characteristics and survival rate using the Cox proportional hazards regression model and the Kaplan-Meier method. Results: Overall Survival (OS, P<0.001) and Cancer-Specific Survival (CSS, P<0.001) were favorably linked with MCHC levels in patients with CCRCC, as depicted by the Kaplan-Meier method. Univariate analysis showed that MCHC was substantially linked with OS [Hazard Ratio (HR)=0.278; 95% Confidence Interval (CI) (0.146-0.530); P<0.001] and CSS [HR=0.244; 95% CI (0.125-0.476); P<0.001] in patients with CCRCC. In multivariate analysis, higher MCHC was linked to better OS [HR=0.296; 95% CI (0.144-0.609); P<0.001] and CSS [HR=0.249; 95% CI (0.116-0.533)); P<0.001], suggesting that preoperative MCHC level is an independent predictor of CCRCC. Conclusion: Our data imply that in patients with CCRCC, preoperative MCHC is a more accurate predictor of OS and CSS.

Keywords

Cite the article

Ou K, Shao Y, Chen C, Zhuang Q. Preoperative Mean Corpuscular Hemoglobin Concentration (MCHC) as Indicators of Patients' Poor Prognosis for Renal Clear Cell Carcinoma. Clin Surg. 2022; 7: 3599..